Form D · Other

Mydecine Innovations Group Inc.

Vancouver, A1 · CIK 0001841626

Offering snapshot reported Jun 15, 2022 · SEC filing

Reported sold: $628K
Investors reported: 1
Minimum accepted: $0
First sale: May 27, 2022

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jun 15, 2022	Initial	$628,078	No comparison	1	SEC filing

Offering details

Securities: Equity, Option to acquire, Security to be acquired, Other
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-449213

"Total Remaining to be Sold" is the aggregate purchase price of shares underlying warrants sold in this offering. U.S. dollar amounts are based on the Bank of Canada exchange rate 0.7851 reported on May 27, 2022.

Each Unit consists of 1 cm sh & 1 cm sh purchase wrt. Each whole wrt entitles the holder to purchase 1 cm sh at a price of CDN$1.40 for a period of 5 years following the closing date.

Source: Form D, filed Jun 15, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Dr. Saeid Babaei	Director
Joshua Bartch	Director, Executive
Dean Ditto	Executive
Dr. Victoria Hale	Director
Dr. Rakesh Jetly	Executive
Damon Michaels	Director, Executive
Gordon Neal	Director
Robert Roscow	Director, Executive
Sanford Stein	Executive
Josephine Wu	Director

Issuer details

Industry: Other (See others in industry)

Address:

810 789 W. Pender Street
Vancouver, A1, V6C 1H2